Who Generates More Revenue? Telix Pharmaceuticals Limited or Ligand Pharmaceuticals Incorporated

Telix Surpasses Ligand in 2023 Revenue Surge

__timestampLigand Pharmaceuticals IncorporatedTelix Pharmaceuticals Limited
Wednesday, January 1, 20146453800028336824
Thursday, January 1, 20157191400032319194
Friday, January 1, 201610897300029404631
Sunday, January 1, 201714110200031769230
Monday, January 1, 201825145300020439380
Tuesday, January 1, 201912028200024186536
Wednesday, January 1, 20201864190004680000
Friday, January 1, 20212771330004898000
Saturday, January 1, 2022196245000155984000
Sunday, January 1, 2023131314000496659000
Loading chart...

Infusing magic into the data realm

Revenue Race: Telix vs. Ligand

In the dynamic world of pharmaceuticals, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Ligand Pharmaceuticals Incorporated and Telix Pharmaceuticals Limited have been pivotal players in this arena. From 2014 to 2023, Ligand consistently outperformed Telix until a dramatic shift in 2023.

A Decade of Change

Ligand's revenue peaked in 2021, reaching nearly 278% of its 2014 figures. However, Telix's revenue skyrocketed by 1,650% from 2014 to 2023, culminating in a remarkable $497 million in 2023, surpassing Ligand's $131 million. This shift highlights Telix's aggressive growth strategy and market adaptation.

The Future Outlook

As the pharmaceutical landscape evolves, Telix's recent surge suggests a promising trajectory. Investors and industry watchers should keep an eye on these companies as they continue to innovate and expand their market reach.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025